Biotech feud over the multibillion-dollar cancer blood test market spills onto social media (STAT)

Guardant Health and Exact Sciences are making significant bets on blood-based tests for colorectal cancer screening. These companies are investing heavily in advancing non-invasive blood tests that could rival or complement existing screening methods like colonoscopies or stool-based tests. The goal is to increase screening rates, especially for those hesitant about traditional methods. However, the high costs of developing and marketing these tests, coupled with questions about their accuracy and regulatory approval, make this a risky but potentially groundbreaking move in cancer diagnostics.